Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07850973) titled 'Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Germ Cell Cancer
Intervention:
Drug: Olaparib
Drug: Gemcitabine
Drug: Docetaxel
Drug: Carboplatin
Drug: Etoposide
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 1, 2027
Target Sample Size: 36
Cou...